使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Align Q1 '22 Earnings Call. (Operator Instructions) Please note this conference will be recorded. I will now turn the conference over to your host, Shirley Stacy with Align Technology. You may begin.
各位好,歡迎參加 Align 2022 年第一季(Q1 '22)財報電話會議。(接線員指示)請注意,本次會議將被錄音。現在我將把會議交給本次會議主持人、Align Technology 的 Shirley Stacy。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Good afternoon. Thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued first quarter 2022 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.
謝謝。各位下午好。感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 GlobeNewswire 發布 2022 年第一季財務結果,您可於我們網站 investor.aligntech.com 查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on May 11. To access the telephone replay, domestic callers should dial (866) 813-9403 with access code 335004. International callers should dial (929) 458-6194 using the same access code.
今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 1 個月。電話重播將於今日約美東時間下午 5:30 起提供,並持續至 5 月 11 日美東時間下午 5:30。若要收聽電話重播,美國境內來電者請撥 (866) 813-9403,輸入存取碼 335004。國際來電者請撥 (929) 458-6194,並使用相同存取碼。
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our form -- in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們向美國證券交易委員會(SEC)提交的最新定期報告中有更詳細的說明,該等文件可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We've posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our first quarter 2022 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
我們已在網站「季度業績」專區張貼歷史財務報表(含相對應之調節表),包括(如適用)GAAP 與非 GAAP 的調節,以及 2022 年第一季財報電話會議簡報。請參閱這些檔案以取得更詳細資訊。
With that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide an overview of our Q1 results and discuss the performance of our 2 operating segments: Systems and Services and Clear Aligners. John will provide more detail on our financial performance and our view for the remainder of the year. Following that, I'll come back and summarize a few key points and open the call to questions.
謝謝,Shirley。各位下午好,感謝加入今天的電話會議。我將先概述我們第一季的業績,並討論兩個營運部門的表現:系統與服務(Systems and Services)以及透明牙套(Clear Aligners)。John 將更詳細說明我們的財務表現,以及對今年剩餘期間的看法。之後我會回來總結幾個重點,並開放提問。
Overall, the first quarter proved to be a tougher-than-expected operating environment globally. And we believe our results primarily reflect 3 key factors: the continued impact of COVID-19 waves in every region and especially in China, with its restrictions and lockdowns under their zero-COVID policy; a weaker economic environment and waning consumer confidence driven by increasing inflationary pressures and supply chain disruptions; and the military conflict in the Ukraine and fallout across Europe.
整體而言,第一季在全球的營運環境比預期更具挑戰。我們認為本季結果主要反映三個關鍵因素:COVID-19 疫情在各地區持續反覆,尤其是中國在「清零」政策下的限制與封控;在通膨壓力上升與供應鏈中斷的推動下,經濟環境轉弱且消費者信心下滑;以及烏克蘭軍事衝突及其在歐洲的外溢影響。
In addition, with approximately half our business occurring outside the United States, unfavorable foreign exchange rates negatively impacting our revenues, margins and EPS. Notwithstanding these headwinds, Q1 '22 total revenues of $973.2 million were up 8.8% year-over-year compared to Q1 '21 revenues of $894 million with a growth rate of 62% year-over-year. Our Q1 '22 operating income was $198 million, and operating margin was 20.4%.
此外,由於約一半業務發生在美國以外,不利的外匯匯率對我們的營收、毛利率與每股盈餘(EPS)造成負面影響。儘管面臨這些逆風,2022 年第一季總營收為 9.732 億美元,較 2021 年第一季的 8.94 億美元年增 8.8%,年增率為 62%。2022 年第一季營業利益為 1.98 億美元,營業利益率為 20.4%。
In Q1, Systems and Services revenues were up 15.6% year-over-year, but down 24% sequentially, coming off our sixth consecutive quarter of sequential growth and record scanner and services revenue. Sequential results primarily reflect lower volumes from our aforementioned headwinds and from seasonality as Q4 is historically a stronger capital equipment sales quarter.
第一季,系統與服務營收年增 15.6%,但較前一季下滑 24%;此前我們已連續六季呈現季增,並創下掃描儀與服務營收新高。季減主要反映前述逆風導致的量能下降,以及季節性因素,因第四季歷來是資本設備銷售較強的季度。
For Q1, Clear Aligner revenues were up 7.5% year-over-year, reflecting revenue growth across regions and products, and were down slightly sequentially from Q4 at minus 0.7%.
第一季,透明牙套營收年增 7.5%,反映各地區與各產品的營收成長;較第四季則小幅季減 0.7%。
In the teen segment, 175,000 teens started treatment with Invisalign aligners, up 6% year-over-year. Invisalign First for kids as young as 6 years old grew sequentially year-over-year and was strong across all regions.
在青少年(teen)族群方面,有 175,000 名青少年開始使用 Invisalign 隱形牙套治療,年增 6%。針對最小 6 歲兒童的 Invisalign First,無論以年比或季比皆呈成長,且在所有地區表現強勁。
Q1 non-case revenues, which include doctor-prescribed retention products, clinical training and education and other dental consumables, performed well and grew both year-over-year and sequentially. Our Doctor Subscription Plan (sic) [Doctor Subscription Program], or DSP, pilot was launched last year in the United States and Canada, and it continues to ramp nicely, driving strong revenue growth.
第一季非病例(non-case)營收(包括醫師處方的維持器產品、臨床訓練與教育,以及其他牙科耗材)表現良好,年比與季比皆成長。我們的 Doctor Subscription Plan(原文如此)[Doctor Subscription Program](DSP)試點計畫於去年在美國與加拿大推出,並持續順利擴大,帶動強勁的營收成長。
DSP is a monthly subscription program designed for a segment of experienced Invisalign doctors who are not regularly using our retainers or low-stage aligners. We're very excited about the feedback and uptake we're seeing, and we'll expand the program into other markets this year.
DSP 是一項每月訂閱方案,專為一群具經驗、但未經常使用我們維持器或低階段牙套的 Invisalign 醫師所設計。我們對目前看到的回饋與採用情況感到非常振奮,並將於今年把該計畫擴展至其他市場。
Here are just a few things some doctors are saying about DSP. Dr. Drew Ferris in Santa Barbara, California, "We have shifted our retention model and workflow. We really like the material, the fit and the precision of the product and having everything in Align systems versus printing in-house and having to maintain it ourselves." Dr. Sandra Tai in Vancouver, Canada, "This program fits my business model very well. I'm able to pass savings to patients."
以下是部分醫師對 DSP 的回饋。加州聖塔芭芭拉的 Drew Ferris 醫師表示:「我們已調整維持器模式與工作流程。我們非常喜歡材料、貼合度與產品精準度,而且把所有流程都放在 Align 系統內,而不是在診所內自行列印並自行維護。」加拿大溫哥華的 Sandra Tai 醫師表示:「這個方案非常符合我的商業模式。我能把節省下來的成本回饋給病患。」
Now let's turn to the specifics around the first quarter results, starting with the Americas. For Q1, Invisalign case volumes were down 1.5% year-over-year. On a sequential basis, Americas case volumes were down 4.3%, primarily reflecting the impact from the COVID-19 waves, first experienced in North America beginning in Q4 '21 and continuing to Q1 and later in Latin America, causing consumers customer staffing shortages and practice closures as well as decreased patient traffic and increased appointment cancellations.
接下來我們來看第一季業績的細節,先從美洲地區開始。第一季,Invisalign 病例量年減 1.5%。以季比來看,美洲病例量季減 4.3%,主要反映 COVID-19 疫情反覆的影響:北美自 2021 年第四季開始出現並延續至第一季;拉丁美洲則較晚發生,造成消費者、客戶人力短缺與診所關閉,同時病患來診量下降、預約取消增加。
The latest data from the Gaidge practice analysis tool that collect and consolidates data from about 700 ortho practices, covering more than 1,000 orthodontists across 1,600 locations in the United States and Canada, showed weakening underlying patient demand trends in the first quarter for both adult and teens and across wires and brackets and clear aligner products. New patient visits were down 7.6% year-over-year, and ortho starts were down 7.2% year-over-year.
來自 Gaidge 診所分析工具的最新數據(該工具蒐集並彙整約 700 家齒顎矯正診所的資料,涵蓋美國與加拿大 1,600 個據點、超過 1,000 位矯正醫師)顯示,第一季成人與青少年族群的基礎病患需求趨勢皆轉弱,且在傳統鋼線與矯正器以及透明牙套產品之間皆然。新病患就診次數年減 7.6%,矯正治療啟動(ortho starts)年減 7.2%。
In the DSO channel, in Q1 '22, DSO practices grew faster than non-DSO practices, with utilization led by Heartland and Smile Doctors. Earlier this month, we announced a new DSO partnership with dentalcorp, Canada's largest and fastest growing network of dental practices. dentalcorp plans to extend its offering of Invisalign brand clear aligner treatment to Canadians nationwide through its Ortho Acceleration Program. This strategic collaboration also provides dentalcorp's network of doctors across nearly 460 practices with access to enhanced benefits, dedicated learning opportunities and treatment planning support for the Invisalign system.
在 DSO 通路方面,2022 年第一季 DSO 診所的成長速度快於非 DSO 診所,使用率由 Heartland 與 Smile Doctors 帶動。本月稍早,我們宣布與 dentalcorp 建立新的 DSO 合作夥伴關係;dentalcorp 是加拿大最大且成長最快的牙科診所網路。dentalcorp 計畫透過其 Ortho Acceleration Program,將 Invisalign 品牌透明牙套治療服務擴展至全加拿大。此一策略合作亦讓 dentalcorp 網路中近 460 家診所的醫師可享有強化的福利、專屬學習機會,以及 Invisalign 系統的治療規劃支援。
Also this month, we launched a new Invisalign Teen Subscription Program in the United States and Canada to help unlock the massive opportunity from teen orthodontics, which makes up approximately 75% of the 5 million annual case starts in North America. The Teen Subscription Program enables orthodontists to buy clear aligners in case packs in advance, much like the way they buy wires and brackets today, offering simple and more predictable billing for doctors.
同樣在本月,我們在美國與加拿大推出全新的 Invisalign Teen Subscription Program,以協助釋放青少年矯正的巨大機會;青少年矯正約占北美每年 500 萬例啟動病例的約 75%。Teen Subscription Program 讓矯正醫師可預先以病例包(case packs)方式購買透明牙套,類似他們目前購買鋼線與矯正器的方式,為醫師提供更簡單且更可預測的計費方式。
It also includes exclusive practice development benefits with the Invisalign brand and requires an incremental volume commitment from doctors. The timing of the new teen program coincides with the beginning of the summer teen season, and we're excited to continue partnering with doctors to grow their practice with Invisalign treatment. With less than 10% share of teen case starts, the Teen Subscription Program has the potential to help accelerate Invisalign adoption in the largest segment of the orthodontic market, teens.
該方案亦包含 Invisalign 品牌的專屬診所發展福利,並要求醫師承諾額外的量能。新青少年方案的推出時點,正好與暑期青少年旺季開始相吻合;我們很高興能持續與醫師合作,透過 Invisalign 治療協助其診所成長。在青少年啟動病例中市占率仍低於 10% 的情況下,Teen Subscription Program 有潛力加速 Invisalign 在矯正市場最大族群——青少年——中的採用。
For our international business, Q1 Invisalign case volumes were up 3% year-over-year. On a sequential basis, international case volumes were down 6.1%, primarily reflecting the headwinds described earlier, especially the impact of COVID-19 restrictions and lockdowns in China and the fallout across Europe from the military conflict in Ukraine.
在國際業務方面,第一季 Invisalign 病例量年增 3%。以季比來看,國際病例量季減 6.1%,主要反映先前所述的逆風,尤其是中國 COVID-19 限制與封控的影響,以及烏克蘭軍事衝突在歐洲造成的外溢影響。
For EMEA, Q1 Invisalign case volumes were up 2.1% year-over-year, with core -- growth in our core markets led by Italy and Germany and DACH, along with the growth expansion markets led by Turkey and MEA. The Q1 year-over-year Invisalign case volume in EMEA was driven by increased submissions, primarily from the orthodontist channel, especially in the teen market.
在 EMEA 地區,第一季 Invisalign 病例量年增 2.1%;核心市場的成長由義大利、德國與 DACH 帶動,成長擴張市場則由土耳其與 MEA 帶動。EMEA 第一季年比 Invisalign 病例量的成長,來自提交量增加,主要來自矯正醫師通路,尤其是在青少年市場。
During the quarter, we launched our first ever direct-to-teen campaign in EMEA focused on educating teens about the benefits of Invisalign treatment over traditional wires and brackets; increasing consumer demand as part of our wider teen growth plan, combined with our Parent of Teen campaign; and to help give teens critical influence in the parent decision by driving peer word-of-mouth.
在本季度期間,我們在 EMEA 推出了史上首次直接面向青少年的行銷活動,重點在於教育青少年了解 Invisalign 療程相較於傳統鋼線與矯正托槽的優勢;作為我們更廣泛的青少年成長計畫的一部分,結合我們的「青少年家長」行銷活動,以提升消費者需求;並透過推動同儕口碑,協助青少年在家長決策中發揮關鍵影響力。
More recently, we launched the Invisalign Go Express system, the latest addition to the Invisalign Go portfolio for general dentists. First launched in EMEA in 2016 as a 20-stage aligner treatment offering, the Invisalign Go portfolio system is designed for general dentists to treat mild to moderate malocclusions and to integrate tooth alignment into restorative and comprehensive dental care. Additionally, building of our European manufacturing facility in Wroclaw, Poland remains on track to go live this quarter, increasing our flexibility and timeliness in supporting our valued doctor customers across the EMEA region.
近期,我們推出 Invisalign Go Express 系統,作為面向一般牙醫的 Invisalign Go 產品組合之最新成員。Invisalign Go 產品組合系統於 2016 年首次在 EMEA 推出,提供最多 20 個階段的隱形矯正療程,旨在讓一般牙醫可治療輕度至中度咬合不正,並將牙齒排列納入修復性與全方位牙科照護。此外,我們位於波蘭弗羅茨瓦夫(Wroclaw)的歐洲製造工廠建置仍按計畫進行,預計將於本季度上線,提升我們在支援 EMEA 區域珍視的醫師客戶時的彈性與即時性。
Turning to APAC for Q1. APAC Invisalign case volumes were up 4.7% year-over-year with strength in the GP dentist channel, primarily through increased Invisalign submissions with the Invisalign Go product and, in the teen market with increased submissions from the orthodontic channel.
接著看 APAC 的第一季。APAC 的 Invisalign 病例量年增 4.7%,其中一般牙醫(GP)通路表現強勁,主要來自 Invisalign Go 產品帶動的 Invisalign 提交量增加;而在青少年市場方面,則來自矯正專科通路提交量的提升。
On a sequential basis, APAC was down 2.6%, reflecting a larger impact from surges in new COVID-19 cases that led to significant lockdowns in China. Alternatively, despite headwinds, Japan and Taiwan performed well and we had strong growth in emerging markets like Korea and India and Thailand on a year-over-year basis.
以季比而言,APAC 下滑 2.6%,反映中國新冠肺炎(COVID-19)新增病例激增所帶來的更大影響,並導致大規模封控。另一方面,儘管面臨逆風,日本與台灣表現良好;且在年比基礎上,我們在韓國、印度與泰國等新興市場亦實現強勁成長。
Earlier this month, we expanded the Invisalign Clear Aligner product portfolio with new offerings that better serve the expanding market in China. The 2 new products, Invisalign Adult and Invisalign Standard clear aligners are designed for more specific types of malocclusion cases and private (sic) [provide] doctors and their patients with a more clinical and affordable options for moderate to complex cases. Invisalign Adult and Invisalign Standard clear aligners built on our proven technology for a wider range and scope of malocclusion.
本月稍早,我們以新產品擴充 Invisalign 透明矯正器產品組合,以更好地服務中國持續擴大的市場。兩項新產品 Invisalign Adult 與 Invisalign Standard 透明矯正器,係針對更特定類型的咬合不正病例所設計,並為醫師及其患者提供更具臨床性且更可負擔的選擇,以應對中度至複雜病例。Invisalign Adult 與 Invisalign Standard 透明矯正器建立在我們經驗證的技術之上,可涵蓋更廣泛的咬合不正範圍與治療面向。
During the quarter, we announced new Invisalign innovations for the Align Digital Platform, a proprietary combination of software, systems and services designed to provide a seamless experience and workflow that integrates and connects all users, doctors, labs, patients and consumers. These new Invisalign innovations include ClinCheck Live Update, the Invisalign Practice App, Invisalign Personalized Plan or IPP, Invisalign Smile Architect and the Cone Beam Computed Tomography, CBCT, integration feature for ClinCheck digital treatment planning software.
在本季度期間,我們宣布 Align 數位平台(Align Digital Platform)的全新 Invisalign 創新功能。該平台為我們的專有軟體、系統與服務之組合,旨在提供無縫體驗與工作流程,整合並連結所有使用者、醫師、技工所、患者與消費者。這些新的 Invisalign 創新功能包括 ClinCheck Live Update、Invisalign Practice App、Invisalign Personalized Plan(IPP)、Invisalign Smile Architect,以及 ClinCheck 數位治療規劃軟體的錐形束電腦斷層(CBCT)整合功能。
These innovations will revolutionize digital treatment planning for orthodontics and restorative dentistry by providing doctors with greater flexibility and real-time treatment plan access and modification capabilities. Each of these innovations is designed to enhance Invisalign treatment planning quality, efficiency and scale and contribute to a better doctor-patient experience.
這些創新將透過提供醫師更高的彈性,以及即時存取與修改治療計畫的能力,徹底革新矯正與修復牙科的數位治療規劃。上述每一項創新皆旨在提升 Invisalign 治療規劃的品質、效率與規模,並帶來更佳的醫病體驗。
More recently, we introduced a new enhancement for the Invisalign system with mandibular advancement feature. The Invisalign system with mandibular advancement is the only clinically proven clear aligner product in the world today that addresses Class II correction with simultaneous alignment. Using feedback from customers, we've enhanced the original design with new enhanced precision wings that provide increased durability and comfort as well as great overlap to help ensure that the aligners remain seated and properly engaged to more effectively address Class II malocclusions in growing preteen and teen patients.
近期,我們為具下顎前移(mandibular advancement)功能的 Invisalign 系統推出新的強化升級。具下顎前移功能的 Invisalign 系統是目前全球唯一經臨床證實可在同步排列牙齒的同時,進行第二類(Class II)咬合矯正的透明矯正器產品。根據客戶回饋,我們以全新強化的精密翼(precision wings)改良原始設計,提升耐用性與舒適度,並提供更佳的重疊貼合,以協助確保矯正器能穩固就位並正確咬合,更有效地處理成長期學齡前兒童與青少年患者的第二類咬合不正。
Our consumer marketing focuses on educating consumers about the Invisalign system and driving that demand to Invisalign doctors' offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles. In Q1, we built on a successful Invis Is multimedia campaign across the Americas, EMEA and APAC, driving awareness and interest in Invisalign treatment with adult, teen and parent consumer segments. Globally, we delivered strong impression volume with over 23.7 million visits to our websites, 113% year-over-year increase and over 7.8 billion impressions delivered, representing a 32% year-over-year increase.
我們的消費者行銷聚焦於教育消費者了解 Invisalign 系統,並將需求導流至 Invisalign 醫師診所,最終把握將 5 億個笑容轉變的龐大市場機會。在第一季,我們延續在美洲、EMEA 與 APAC 推出的成功「Invis Is」多媒體行銷活動,提升成人、青少年與家長等消費者族群對 Invisalign 療程的認知與興趣。全球而言,我們帶來強勁的曝光量:網站造訪次數超過 2,370 萬次,年增 113%;投放曝光(impressions)超過 78 億次,年增 32%。
In the U.S., we continue to amplify our campaigns across the top social platforms such as TikTok, Snapchat, Instagram and YouTube to increase the awareness of Invisalign brand with young adults and teens. Our campaigns featured collaborations with some of the largest influencers in social media, including Charli D'Amelio, Lana Candor, Devan Key, Michael Le and Josh Richards. Each of these creators shared their personal experience with Invisalign treatment and why they chose to transform their smiles with Invisalign aligners.
在美國,我們持續在 TikTok、Snapchat、Instagram 與 YouTube 等主要社群平台擴大行銷活動,以提升年輕成人與青少年對 Invisalign 品牌的認知。我們的活動與多位社群媒體頂尖影響者合作,包括 Charli D'Amelio、Lana Candor、Devan Key、Michael Le 與 Josh Richards。這些創作者各自分享其 Invisalign 療程的親身體驗,以及他們為何選擇透過 Invisalign 隱形矯正器改變自己的笑容。
To continue growing our young adult business across the Americas, EMEA and APAC, we built upon our successful "Invis is a Powerful Thing" campaign, which highlights how powerful the smile transformation with Invisalign treatment can be for even young adults' self-confidence. We leveraged top influencers like Leilani Green and Lana Candor in integrated media campaigns. Further, we are expanding our collaboration with influencers globally and are excited to welcome Olympic Gold Medalist, Suni Lee, and creators Josh Richards, Hyram Yarbro and Scarlett Estevez who have chosen to shape their smiles with Invisalign treatment.
為持續在美洲、EMEA 與 APAC 擴大我們的年輕成人業務,我們在成功的「Invis is a Powerful Thing」行銷活動基礎上再接再厲,強調即使對年輕成人而言,透過 Invisalign 療程帶來的笑容轉變也能大幅提升自信。我們在整合式媒體活動中運用 Leilani Green 與 Lana Candor 等頂尖影響者。此外,我們正於全球擴大與影響者的合作,並很高興歡迎奧運金牌得主 Suni Lee,以及創作者 Josh Richards、Hyram Yarbro 與 Scarlett Estevez;他們已選擇透過 Invisalign 療程塑造自己的笑容。
In the EMEA region, we accelerated our media investments across digital media platforms, including YouTube, TikTok, Meta and Snapchat and expanded our Invisalign Smile Squad roster with new influencers. Additionally, we launched a pilot in the U.K. to reach teens with special campaigns to create awareness of the unique benefits of Invisalign treatment. Our consumer campaigns delivered more than 8.8 million unique visitors to our website, representing 170% increase year-over-year with over 2.5 billion media impressions.
在 EMEA 地區,我們加速在數位媒體平台(包括 YouTube、TikTok、Meta 與 Snapchat)的媒體投資,並以新影響者擴充 Invisalign Smile Squad 名單。此外,我們在英國啟動試點計畫,透過專屬行銷活動觸及青少年,以建立對 Invisalign 療程獨特優勢的認知。我們的消費者行銷活動為網站帶來超過 880 萬名不重複訪客,年增 170%,並投放超過 25 億次媒體曝光。
We continue to expand our investment in consumer advertising across the APAC region, excluding China, resulting in a 278% increase year-over-year in unique visitors and a 265% year-over-year increase in impressions. We continued to strengthen our investments in Australia by expanding our reach via social media platforms such as TikTok, Meta and YouTube. In Japan, we built upon our successful consumer campaigns by expanding into Twitter and continue to see strong response from consumers, as evidenced by a 373% increase in unique visitors to our site.
我們持續擴大在 APAC 地區(不含中國)的消費者廣告投資,使不重複訪客年增 278%,曝光量年增 265%。我們也持續強化在澳洲的投資,透過 TikTok、Meta 與 YouTube 等社群平台擴大觸及。在日本,我們在既有成功的消費者行銷活動基礎上擴展至 Twitter,並持續看到消費者的強勁回應,網站不重複訪客增加 373% 即為明證。
For our Systems and Services business, Q1 revenues were up 15.6% year-over-year, reflecting strong scanner shipments and services; and down 24.2% sequentially, primarily reflecting lower volumes from the previous mentioned headwinds and capital equipment seasonality.
就我們的系統與服務(Systems and Services)業務而言,第一季營收年增 15.6%,反映掃描儀出貨與服務表現強勁;但季減 24.2%,主要反映前述逆風導致的量能下降,以及資本設備的季節性因素。
During the quarter, we saw continued adoption of the iTero Element 5D Plus imaging system we launched last year that features innovative technology like Near Infra-Red technology that we call NIRI, which aids in detection and monitoring of interproximal caries lesions or cavities without -- above the gingiva without harmful radiation.
在本季度期間,我們看到去年推出的 iTero Element 5D Plus 影像系統持續被採用;該系統具備我們稱為 NIRI 的近紅外線(Near Infra-Red)等創新技術,可在不使用有害輻射的情況下,協助偵測與監測牙間鄰接面齲齒病灶或蛀牙——位於牙齦以上的區域。
A strong indicator of the digital adoption within dental offices is the number of intraoral scans used for Invisalign case submissions. Total worldwide intraoral digital scans submitted to start an Invisalign case in Q1 increased to 87.1% from 80.9% in Q1 last year. International intraoral digital scans for Invisalign case submissions increased to 83%, up from 75% in Q1 last year.
衡量牙科診所數位化採用程度的一項重要指標,是用於提交 Invisalign 病例的口內掃描數量。第一季,全球用於啟動 Invisalign 病例提交的口內數位掃描占比提升至 87.1%,高於去年第一季的 80.9%。國際市場用於 Invisalign 病例提交的口內數位掃描占比提升至 83%,高於去年第一季的 75%。
For the Americas, 91% of Invisalign cases were submitted using an intraoral digital scan compared to 85.5% in Q1 of last year. Cumulatively, over 54.9 million orthodontic scans and over 11.4 million restorative scans have been performed with iTero scanners.
在美洲地區,91% 的 Invisalign 病例以口內數位掃描提交,相較於去年第一季的 85.5%。累計而言,已透過 iTero 掃描儀完成超過 5,490 萬次矯正掃描,以及超過 1,140 萬次修復掃描。
During the quarter, the iTero Element 5D Plus won the Best New Imaging or CAD/CAM Product from DrBicuspid.com, a Cuspie award. The award reflects our commitment to develop innovative solutions that help doctors transform lives by improving patients' journey to a healthy, beautiful smile. We are pleased to share that the iTero Element scanner received an Orthotown 2021 Townie Choice Award, which seeks to recognize the top peer-recommended products and services in dentistry. We're proud that the iTero Element 5D Plus imaging system provides dental practices with latest in imaging technology, cutting-edge enhanced chairside visualizations and applications that can drive practice growth and treatment acceptance.
在本季度期間,iTero Element 5D Plus 榮獲 DrBicuspid.com 頒發的「最佳新影像或 CAD/CAM 產品」Cuspie 獎。該獎項反映我們致力於開發創新解決方案,協助醫師透過改善患者邁向健康、美麗笑容的歷程來改變人生。我們也很高興分享,iTero Element 掃描儀獲得 Orthotown 2021 Townie Choice Award,該獎項旨在表彰牙科領域中同儕推薦的頂尖產品與服務。我們以 iTero Element 5D Plus 影像系統能為牙科診所提供最新影像技術、先進的椅旁視覺化增強功能與應用,進而推動診所成長與提升治療接受度而深感自豪。
Continued growth in the iTero scanner installed base is driving increased services revenues as well as exocad CAD/CAM software solutions that integrate workflows to the dental labs and dental practices.
iTero 掃描儀裝機基數持續成長,正帶動服務營收增加,以及可將工作流程整合至牙科技工所與牙科診所的 exocad CAD/CAM 軟體解決方案。
Our Q1 exocad CAD/CAM products and services, which include restorative dentistry, implantology, guided surgery and smile design offerings, are included in Scanner and Services revenues and are helping extend our digital dental solutions and broaden Align Digital Platform towards fully integrated interdisciplinary end-to-end workflows.
我們第一季的 exocad CAD/CAM 產品與服務(包含修復牙科、植牙學、導引手術與微笑設計等方案)計入「掃描儀與服務」營收,並有助於延伸我們的數位牙科解決方案,推動 Align 數位平台朝向完全整合、跨專科的端到端工作流程發展。
As we continue to lead the evolution of digital orthodontics and restorative dentistry, our goal is to make orthodontics a pillar of dentistry. April 2 marked our second anniversary since welcoming exocad into the Align family. And together, we're working to ensure that every dental technician and every dentist planning a restorative treatment considers the benefits of digital orthodontics first. We're continuing to focus on integration and road map development to strengthen the Align Digital Platform by addressing restorative needs to facilitate both ortho restorative and comprehensive dentistry.
在我們持續引領數位矯正與修復牙科演進之際,我們的目標是讓矯正成為牙科的一大支柱。4 月 2 日是我們迎接 exocad 加入 Align 大家庭的第二週年。透過雙方合作,我們致力於確保每位牙科技工師與每位規劃修復治療的牙醫師,都能優先考量數位矯正的效益。我們將持續聚焦整合與路線圖開發,透過滿足修復需求來強化 Align 數位平台,以促進矯正與修復並行以及全方位牙科。
Two years after exocad joined Align, we are more excited than ever about the opportunities ahead to shape the dental industry and with technology and expertise that complement the many benefits of the Align Digital Platform and bringing all key stakeholders together, doctor, customers, labs, partners and users as we continue transforming smiles and changing lives.
exocad 加入 Align 兩年後,我們對於未來能以技術與專業形塑牙科產業的機會比以往更感振奮;這些技術與專業可與 Align 數位平台的多項優勢相輔相成,並在我們持續改變笑容、改變人生的同時,將所有關鍵利害關係人——醫師、客戶、技工所、合作夥伴與使用者——凝聚在一起。
During the quarter, exocad participated in the 2022 Dental South China show in Guangzhou, China, showcasing its newest software release, DentalCAD 3.0 Galway plus other open software solutions like innovative smile design program called Smile Creator. The show allowed the exocad team to deepen their relationships with the dental community to discover new trends emerging in the growing dental market in China. Attendees at booth experienced firsthand how exocad's wizard-guided workflows and easy online communication programs streamline the treatment journey from consultation to final restoration.
本季期間,exocad 參與在中國廣州舉辦的 2022 華南國際口腔展,展示其最新軟體版本 DentalCAD 3.0 Galway,以及其他開放式軟體解決方案,例如名為 Smile Creator 的創新微笑設計程式。該展會讓 exocad 團隊得以深化與牙科社群的關係,並探索中國成長中牙科市場的新興趨勢。攤位參觀者也親身體驗 exocad 的精靈引導式工作流程與便捷的線上溝通程式,如何將治療旅程從諮詢到最終修復加以簡化。
Finally, this quarter, exocad is opening its new headquarters in Seoul, South Korea, which provides a robust high-tech infrastructure to a key region of our business. exocad has been working with a growing number of Korean manufacturers for many years, and this location help facilitate strategic relationships in the region.
最後,本季 exocad 將在韓國首爾啟用新總部,為我們業務的關鍵區域提供強健的高科技基礎設施。多年來,exocad 一直與日益增加的韓國製造商合作,而此據點有助於促進該地區的策略性關係。
With that, I'll now turn over the call to John.
接下來,我把電話會議交給 John。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Thanks, Joe. Now for our Q1 financial results. Total revenues for the first quarter were $973.2 million, down 5.6% from the prior quarter and up 8.8% from the corresponding quarter a year ago. For Clear Aligners, Q1 revenues of $809.7 million were down 0.7% sequentially due to lower Invisalign case volumes, partially offset by higher ASPs and up 7.5% year-over-year, reflecting higher ASPs and non-case revenues.
謝謝,Joe。接著說明我們第一季的財務結果。第一季總營收為 9.732 億美元,較前一季下降 5.6%,較去年同期增加 8.8%。在透明牙套(Clear Aligners)方面,第一季營收為 8.097 億美元,因 Invisalign 病例量較低而較前一季下降 0.7%,但部分被較高的平均售價(ASP)所抵銷;較去年同期增加 7.5%,反映較高的 ASP 與非病例營收。
In Q1, Invisalign case volume were down 5.1% sequentially and up 0.5% year-over-year. In addition, we shipped Clear Aligners to 82,400 Invisalign doctors worldwide, of which over 5,000 were first-time customers. Q1 comprehensive volume increased 2.4% year-over-year and decreased 5% sequentially. Q1 non-comprehensive volume decreased 4% year-over-year and decreased 5.4% sequentially. Q1 adult patients decreased 1.6% year-over-year and decreased 5.7% sequentially. In Q1, teens or younger patients increased 6% year-over-year and decreased 3.6% sequentially.
第一季 Invisalign 病例量較前一季下降 5.1%,較去年同期增加 0.5%。此外,我們向全球 82,400 位 Invisalign 醫師出貨透明牙套,其中超過 5,000 位為首次購買客戶。第一季綜合型(comprehensive)量較去年同期增加 2.4%,較前一季下降 5%。第一季非綜合型(non-comprehensive)量較去年同期下降 4%,較前一季下降 5.4%。第一季成人患者較去年同期下降 1.6%,較前一季下降 5.7%。第一季青少年或更年輕患者較去年同期增加 6%,較前一季下降 3.6%。
Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $6.5 million or approximately 0.8 points sequentially. On a year-over-year basis, Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $24 million or approximately 3.2 points.
透明牙套營收受到外匯不利影響,約 650 萬美元,或較前一季約 0.8 個百分點。以年對年來看,透明牙套營收受到外匯不利影響約 2,400 萬美元,或約 3.2 個百分點。
For Q1, Invisalign comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign comprehensive ASPs reflect per order processing fees charged on most Clear Aligner shipments, lower discounts and higher additional aligners, partially offset by unfavorable foreign exchange. On a year-over-year basis, comprehensive ASPs reflect higher additional aligners and per order processing fees, partially offset by unfavorable foreign exchange.
第一季 Invisalign 綜合型 ASP 較前一季及較去年同期均上升。就季對季而言,Invisalign 綜合型 ASP 反映對多數透明牙套出貨收取的每筆訂單處理費、折扣降低與額外牙套增加,部分被外匯不利影響所抵銷。就年對年而言,綜合型 ASP 反映額外牙套增加與每筆訂單處理費,部分被外匯不利影響所抵銷。
Q1 Invisalign non-comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign non-comprehensive ASPs were favorably impacted by per order processing fees and lower discounts, partially offset by unfavorable foreign exchange. On a year-over-year basis, Invisalign non-comprehensive ASPs reflect per order processing fees, higher additional aligners, partially offset by foreign exchange.
第一季 Invisalign 非綜合型 ASP 較前一季及較去年同期均上升。就季對季而言,Invisalign 非綜合型 ASP 受每筆訂單處理費與折扣降低的有利影響,部分被外匯不利影響所抵銷。就年對年而言,Invisalign 非綜合型 ASP 反映每筆訂單處理費與額外牙套增加,部分被外匯影響所抵銷。
Clear Aligner deferred revenues on the balance sheet increased $53 million or 5% sequentially and $307.1 million or 38.1% year-over-year and will be recognized as the additional aligners are shipped.
資產負債表上的透明牙套遞延收入較前一季增加 5,300 萬美元或 5%,較去年同期增加 3.071 億美元或 38.1%,並將在額外牙套出貨時認列。
Our Systems and Services revenue for the first quarter were $163.5 million, down 24.2% sequentially and up 15.6% year-over-year. The decrease sequentially can be attributed to lower scanner volume following a strong Q4 and consistent with seasonality in the capital equipment business, coupled with the headwinds described earlier. The increase year-over-year can be attributed to increased services revenue from our larger installed base as well as slightly higher scanner volume.
第一季「系統與服務」營收為 1.635 億美元,較前一季下降 24.2%,較去年同期增加 15.6%。季對季下降可歸因於在強勁的第四季之後掃描儀出貨量較低,且符合資本設備業務的季節性,再加上先前所述的不利因素。年對年增加可歸因於因裝機基數擴大而帶來的服務營收增加,以及掃描儀出貨量略為提高。
Our Systems and Services deferred revenues on the balance sheet was up $16.5 million or 7.2% sequentially and up $114.9 million or 87.6% year-over-year, primarily due to the increase in scanner sales and the deferral of service revenue included with our -- with the scanner purchase, which will be recognized ratably over the service period.
資產負債表上的「系統與服務」遞延收入較前一季增加 1,650 萬美元或 7.2%,較去年同期增加 1.149 億美元或 87.6%,主要由於掃描儀銷售增加,以及隨掃描儀購買所包含的服務營收遞延所致;該等遞延收入將在服務期間內按比例認列。
Moving on to gross margin. First quarter overall gross margin was 72.9%, up 0.7 points sequentially and down 2.8 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense and amortization of intangibles related to acquisitions, overall gross margin was 73.3% for the first quarter, up 0.7 points sequentially and down 2.8 points year-over-year. Overall gross margin was unfavorably impacted by approximately 0.8 points on a year-over-year basis and by approximately 0.2 points sequentially due to foreign exchange.
接著談毛利率。第一季整體毛利率為 72.9%,較前一季上升 0.7 個百分點,較去年同期下降 2.8 個百分點。以非 GAAP 基礎(排除股份基礎給付費用及與併購相關之無形資產攤銷)計算,第一季整體毛利率為 73.3%,較前一季上升 0.7 個百分點,較去年同期下降 2.8 個百分點。整體毛利率在年對年基礎上約受到外匯 0.8 個百分點的不利影響,季對季約受到外匯 0.2 個百分點的不利影響。
Clear Aligner gross margin for the first quarter was 74.8%, up 0.6 points sequentially due to higher ASPs, partially offset by higher mix of additional aligner volume and higher freight costs. Clear Aligner gross margin was down 2.8 points year-over-year due to higher mix of additional aligner volume and higher freight costs, partially offset by higher ASPs.
第一季透明牙套毛利率為 74.8%,較前一季上升 0.6 個百分點,主因 ASP 較高,部分被額外牙套出貨量占比提高及運費成本上升所抵銷。透明牙套毛利率較去年同期下降 2.8 個百分點,主因額外牙套出貨量占比提高及運費成本上升,部分被 ASP 較高所抵銷。
Systems and Services gross margin for the first quarter was 63.4%, down 1.3 points sequentially due to lower volume and lower ASPs, partially offset by lower freight costs. Systems and Services gross margin was down 2 points year-over-year due to higher manufacturing inefficiencies, partially offset by a higher mix of service revenues and increased ASPs.
第一季「系統與服務」毛利率為 63.4%,較前一季下降 1.3 個百分點,主因出貨量較低與 ASP 較低,部分被運費成本降低所抵銷。「系統與服務」毛利率較去年同期下降 2 個百分點,主因製造效率不佳增加,部分被服務營收占比提高與 ASP 增加所抵銷。
Q1 operating expenses were $511.3 million, down sequentially 2.4% and up 13.2% year-over-year. On a sequential basis, operating expenses were down $12.4 million. Year-over-year, operating expenses increased by $59.6 million, reflecting increased headcount and our continued investment in marketing, sales and R&D activities and investments commensurate with business growth.
第一季營業費用為 5.113 億美元,較前一季下降 2.4%,較去年同期增加 13.2%。就季對季而言,營業費用減少 1,240 萬美元。就年對年而言,營業費用增加 5,960 萬美元,反映人力增加,以及我們持續投資於行銷、銷售與研發活動,並隨業務成長進行相應投資。
On a non-GAAP basis, excluding stock-based compensation, amortization of acquired intangibles related to certain acquisitions and acquisition costs, operating expenses were $480.2 million, down sequentially 2.9% and up 13.1% year-over-year due to the reasons described above.
以非 GAAP 基礎(排除股份基礎給付、與特定併購相關之取得無形資產攤銷及併購成本)計算,營業費用為 4.802 億美元,較前一季下降 2.9%,較去年同期增加 13.1%,原因如上所述。
Our first quarter operating income of $198.1 million resulted in an operating margin of 20.4%, down 1.1 points sequentially and down 4.8 points year-over-year. The year-over-year decrease in operating margin is primarily attributed to lower gross margin, investments in our go-to-market teams and technology as well as unfavorable impact from foreign exchange. On a non-GAAP basis, which excludes stock-based compensation, amortization of intangibles related to certain acquisitions and acquisition costs, operating margin for the first quarter was 24%, down 0.7 points sequentially and down 4.6 points year-over-year.
第一季營業利益為 1.981 億美元,營業利益率為 20.4%,較前一季下降 1.1 個百分點,較去年同期下降 4.8 個百分點。年對年營業利益率下降主要歸因於毛利率較低、對我們市場拓展團隊與技術的投資,以及外匯的不利影響。以非 GAAP 基礎(排除股份基礎給付、與特定併購相關之無形資產攤銷及併購成本)計算,第一季營業利益率為 24%,較前一季下降 0.7 個百分點,較去年同期下降 4.6 個百分點。
Interest and other income and expense, net for the first quarter, was a loss of $10.6 million, down sequentially by $9.7 million and down year-over-year by $46.8 million. Q1 of 2021 included the SEC arbitration award gain of $43.4 million.
第一季利息及其他收入與費用(淨額)為虧損 1,060 萬美元,較前一季減少 970 萬美元,較去年同期減少 4,680 萬美元。2021 年第一季包含 SEC 仲裁裁決收益 4,340 萬美元。
The GAAP effective tax rate for the first quarter was 28.4% compared to 13.2% in the fourth quarter and 23.4% in the first quarter of the prior year. Our non-GAAP effective tax rate was 24.2% in the first quarter compared to 11.5% in the fourth quarter and 20.2% in the first quarter of the prior year. The first quarter GAAP and non-GAAP effective tax rates were higher than fourth quarter effective tax rates, primarily due to tax benefits related to expiration of statutes of limitations for timely asserting claims and an out-of-period adjustment recorded last quarter.
第一季 GAAP 有效稅率為 28.4%,相較第四季的 13.2% 以及去年同期第一季的 23.4%。我們的非 GAAP 有效稅率第一季為 24.2%,相較第四季的 11.5% 以及去年同期第一季的 20.2%。第一季 GAAP 與非 GAAP 有效稅率高於第四季,主要係因與及時主張權利之訴訟時效到期相關的稅務利益,以及上一季入帳的一項跨期調整所致。
First quarter net income per diluted share was $1.70, down sequentially $0.70 and down $0.81 compared to the prior year. Our EPS was unfavorably impacted by $0.13 on a sequential basis and $0.28 on a year-over-year basis due to foreign exchange. On a non-GAAP basis, net income per diluted share was $2.13 for the first quarter, down $0.70 sequentially and down $0.36 year-over-year.
第一季稀釋後每股淨利為 1.70 美元,較前一季減少 0.70 美元,較去年同期減少 0.81 美元。由於外匯因素,我們的 EPS 在季比基礎上不利影響 0.13 美元,在年比基礎上不利影響 0.28 美元。以非 GAAP 基礎計,第一季稀釋後每股淨利為 2.13 美元,較前一季減少 0.70 美元,較去年同期減少 0.36 美元。
Moving on to the balance sheet. As of March 31, 2022, cash, cash equivalents and short-term and long-term marketable securities were $1.1 billion, down sequentially $176.1 million and down $11.1 million year-over-year. Of our $1.1 billion balance, $453 million was held in the U.S. and $667.6 million was held by our international entities.
接著看資產負債表。截至 2022 年 3 月 31 日,現金、約當現金以及短期與長期有價證券為 11 億美元,較前一季減少 1.761 億美元,較去年同期減少 1,110 萬美元。在我們 11 億美元的餘額中,4.53 億美元持有於美國,6.676 億美元由我們的國際實體持有。
Q1 accounts receivable balance was $950.9 million, up approximately 6% sequentially. Our overall days sales outstanding was 87 days, up approximately 9 days sequentially and up approximately 15 days as compared to Q1 last year. Cash flow from operations for the first quarter was $30.5 million. Capital expenditures for the first quarter were $87.3 million, primarily related to our continued investment to increase aligner manufacturing capacity and facilities.
第一季應收帳款餘額為 9.509 億美元,較前一季約增加 6%。整體應收帳款週轉天數(DSO)為 87 天,較前一季約增加 9 天,較去年第一季約增加 15 天。第一季營運活動現金流量為 3,050 萬美元。第一季資本支出為 8,730 萬美元,主要與我們持續投資以提升隱形矯正器製造產能與設施相關。
Free cash flow, defined as cash flow from operations less capital expenditures, amounted to negative $56.8 million. In February, we repurchased $75 million of our common stock through open market repurchases of approximately 143,600 shares at an average price of $522.61 per share. We have approximately $650 million remaining available for repurchase under our May 13, 2021, $1 billion repurchase program.
自由現金流量(定義為營運活動現金流量減資本支出)為負 5,680 萬美元。2 月,我們透過公開市場回購約 143,600 股普通股,以每股平均 522.61 美元的價格回購 7,500 萬美元。我們在 2021 年 5 月 13 日啟動的 10 億美元回購計畫下,尚餘約 6.5 億美元可供回購。
As described during our Q4 2021 earnings call, we provided our fiscal year 2022 outlook with revenue growth in line with our long-term revenue range of 20% to 30%. This revenue growth assumed no significant new COVID surges after current wave, no meaningful practice disruption nor material supply chain issues throughout the year.
如同我們在 2021 年第四季財報電話會議中所述,我們提供了 2022 會計年度展望,營收成長與我們長期 20% 至 30% 的營收區間一致。此營收成長假設在目前這波之後不會出現重大的新一波 COVID 激增、全年不會出現顯著的診所營運中斷,亦不會發生重大的供應鏈問題。
At that time, we were seeing some recovery as Omicron headwinds began to ease and COVID restrictions were relaxing. However, later in the quarter, unfavorable impacts on our business occurred, driven by China lockdowns, weaker consumer confidence, inflationary pressures and the Russia-Ukraine conflict. For April, we have not seen momentum return as the headwinds previously mentioned persist.
當時,隨著 Omicron 的逆風開始緩解且 COVID 限制逐步放寬,我們看到一些復甦。然而在該季後段,受中國封控、消費者信心轉弱、通膨壓力以及俄烏衝突所驅動,我們的業務出現不利影響。就 4 月而言,由於前述逆風仍在,我們尚未看到動能回升。
Now turning to full year 2022. We remain confident in the huge under-penetrated market, our technology and industry leadership and our ability to execute and make progress toward our long-term model of 20% to 30% revenue growth. At the same time, the headwinds we're experiencing, which include increased COVID waves and significant China lockdowns, weaker consumer confidence, inflation pressures and the Russia-Ukraine conflict, have increased uncertainty across all markets. We also anticipate capital equipment sales will be increasingly constrained throughout the year as practices adjust to these headwinds.
接著談 2022 全年。我們仍對龐大且滲透率偏低的市場、我們的技術與產業領導地位,以及我們的執行能力充滿信心,並將持續朝長期 20% 至 30% 的營收成長模型推進。同時,我們正面臨的逆風(包括 COVID 疫情波次增加與中國大規模封控、消費者信心轉弱、通膨壓力以及俄烏衝突)已提高所有市場的不確定性。我們也預期,隨著診所因應這些逆風調整,資本設備銷售在全年將愈發受到限制。
Given less visibility and an increasing unpredictable operating environment, we are not providing revenue guidance for the year. However, assuming no additional material disruptions or circumstances beyond our control, our goal for fiscal 2022 is to deliver GAAP operating margin above 20%, while making strategic investments in sales, marketing, R&D and operations.
鑑於能見度降低且營運環境愈加難以預測,我們不提供全年營收指引。然而,在假設不會出現任何額外的重大干擾或超出我們控制範圍的情況下,我們 2022 會計年度的目標是在進行銷售、行銷、研發與營運的策略性投資同時,達成 GAAP 營業利益率高於 20%。
In addition, during Q2 '22, we expect to repurchase up to $200 million of our common stock through either a combination of open market repurchases or an accelerated stock repurchase agreement.
此外,在 2022 年第二季期間,我們預期將透過公開市場回購或加速股票回購協議的組合,回購最多 2 億美元的普通股。
For 2022, we expect our investments in capital expenditures to exceed $300 million. Capital expenditures primarily relate to building construction and improvements as well as digital manufacturing capacity to support our international expansion. This includes our investment in an aligner fabrication facility in Wroclaw, Poland, which is expected to begin serving doctors in the second quarter of 2022 as part of our strategy to bring operational facilities closer to customers.
2022 年,我們預期資本支出投資將超過 3 億美元。資本支出主要與建築施工與改善,以及支援國際擴張的數位製造產能相關。其中包括我們在波蘭弗羅茨瓦夫(Wroclaw)的隱形矯正器製作設施投資,預計將於 2022 年第二季開始為醫師提供服務,作為我們將營運設施更貼近客戶之策略的一部分。
As we continue growing, we intend to expand our investments in research and development, manufacturing, treatment planning, sales and marketing operations to meet the actual and anticipated local and regional demands.
隨著我們持續成長,我們計畫擴大在研發、製造、治療規劃、銷售與行銷營運方面的投資,以滿足實際與預期的在地及區域需求。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交還給 Joe 做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John.
謝謝你,John。
Operator
Operator
Excuse me. Joe Hogan, are you there?
不好意思。Joe Hogan,你在線上嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. I'll run by this again. Okay. That was my fault. Overall, our first quarter results reflect a more challenging environment than expected. We know that COVID lockdowns, weaker consumer confidence, inflationary pressures and the Russia-Ukraine conflict have created headwinds. But we remain excited and committed to realizing the enormous opportunity in front of us to lead the evolution of digital orthodontics and comprehensive dentistry.
謝謝你,John。我再說一次。好。那是我的疏失。整體而言,我們第一季的結果反映出比預期更具挑戰的環境。我們知道,COVID 封控、消費者信心轉弱、通膨壓力以及俄烏衝突造成了逆風。但我們仍對眼前龐大的機會感到振奮並致力於實現:引領數位正畸與全方位牙科的演進。
With less than 10% share of the 21 million orthodontic case starts each year with over 500 million people globally who can benefit from a healthy, beautiful smile, our market is as large as ever. No other company is as well positioned as us to take advantage of that potential as the environment improves and growth trends return.
在每年 2,100 萬例正畸新啟動病例中,我們的市占率不到 10%;全球有超過 5 億人可受益於健康、美麗的笑容,我們的市場規模依然空前龐大。隨著環境改善、成長趨勢回歸,沒有任何公司能像我們一樣具備如此優勢來把握這項潛力。
We will continue to focus on the execution of our strategic growth drivers while managing investments in the near term to account for the headwinds and uncertainty, and we remain confident in our long-term revenue growth model of 20% to 30%.
我們將持續專注於策略性成長驅動因素的執行,同時在短期內管理投資以因應逆風與不確定性;我們仍對長期 20% 至 30% 的營收成長模型充滿信心。
Before we open the call to questions, I want to address the military conflict in the Ukraine and our operations in Russia. It's a human tragedy for all people involved, and our thoughts go out to everyone impacted and especially to those with personal connections who are undoubtedly concerned with their families and loved ones. Our primary concern remains the safety and security of our employees and their families, our doctors, their staff and patients. We have nothing to do with this conflict.
在我們開放提問之前,我想談談烏克蘭的軍事衝突以及我們在俄羅斯的營運。這對所有相關人士而言都是一場人道悲劇;我們的心與所有受影響的人同在,尤其是那些與當地有個人連結、無疑正為家人與摯愛擔憂的人。我們最主要的關切仍是員工及其家人的安全與保障,以及我們的醫師、其員工與病患的安全與保障。我們與這場衝突無關。
As a global medical device provider of doctor-prescribed products, continuity of care is critical to the doctors and their patients in orthodontic treatment. We discontinued commercial activities in Russia that are not essential to providing continuity of care to patients. Our focus on only essential activities is consistent with our values and ethical responsibility to patients in treatment.
作為提供醫師處方產品的全球醫療器材供應商,在正畸治療中,照護的連續性對醫師及其病患至關重要。我們已停止在俄羅斯不屬於維持病患照護連續性所必需的商業活動。我們僅聚焦於必要活動,符合我們的價值觀以及對治療中病患的倫理責任。
In the process, we're also adhering to the international sanctions that have been imposed. Our IT infrastructure, including code and intellectual property, is hosted outside of Russia. Prior to the conflict, we had begun expanding our R&D teams in Darmstadt, Germany; Madrid, Spain; Toronto, Canada and Austin, Texas. And we're prudently working with the team on the ground in Russia on work visas.
在此過程中,我們也遵循已施加的國際制裁。我們的 IT 基礎設施(包括程式碼與智慧財產)託管於俄羅斯境外。衝突發生前,我們已開始在德國達姆施塔特(Darmstadt)、西班牙馬德里、加拿大多倫多以及德州奧斯汀擴編研發團隊。同時,我們也正審慎地與俄羅斯當地團隊就工作簽證事宜合作。
A number of our Russian employees have already transitioned and are in various stages of transitioning their families to Armenia, where we've set up an R&D center in Yerevan to support those who choose to relocate. At the same time, it's humbling to see the tremendous outpouring of kindness and support throughout the company as our employees respond to the humanitarian needs of the crisis.
我們有多位俄羅斯員工已完成轉移,另有多位正處於將其家人轉移至亞美尼亞的不同階段;我們已在葉里溫(Yerevan)設立研發中心,以支援選擇搬遷的人。同時,看到公司內部在員工回應此次危機的人道需求時所展現的大量善意與支持,令人感到謙卑。
Our Polish team members has set up donation centers at our facilities where employees are contributing food, clothing, supplies and human care. Many are also taking Ukrainian refugees into their homes. And we're proud of the tremendous initiative by our colleagues and are grateful for their actions.
我們的波蘭團隊成員已在我們的設施設立捐贈中心,員工捐出食物、衣物、物資以及人道關懷。許多人也將烏克蘭難民接到家中安置。我們為同仁展現的巨大主動性深感自豪,並感謝他們的行動。
In addition to our employees' efforts, Align is donating $300,000 to support humanitarian relief efforts through organizations providing shelter, food, medicines and vital supplies. We can only hope that the conflict in Ukraine will end soon, that the ongoing impact of the pandemic will lessen for good and that economic factors facing many customers and consumers will abate. But these things are beyond our control, so we will continue to prioritize the health and safety of employees, customers and patients and will stay focused on strategic initiatives.
除了員工的努力之外,Align 也捐贈 30 萬美元,透過提供庇護所、食物、藥品與重要物資的組織,支持人道救援工作。我們只能期盼烏克蘭的衝突能盡快結束、疫情的持續影響能永久減輕,以及許多客戶與消費者所面臨的經濟因素能有所緩解。但這些都非我們所能掌控,因此我們將持續把員工、客戶與病患的健康與安全放在首位,並專注於策略性計畫。
In closing, April 3 marked the 25th anniversary of the founding of Align Technology and, shortly thereafter, the launch of the Invisalign system. Over the past 25 years, we've transformed the orthodontic industry with a passion for innovation as we've evolved from leading the evolution from digital appliances to digital platform. We've created an incredible company unlike any other.
最後,4 月 3 日是 Align Technology 成立 25 週年,而不久之後也推出了 Invisalign 系統。在過去 25 年裡,我們以對創新的熱情改變了齒顎矯正產業;我們從引領數位化器械的演進,進一步發展為引領數位平台的演進。我們打造了一家與眾不同、令人驚嘆的公司。
Invisalign is a unique mass customization business operating in real time with no inventory or distribution at the front end of our market. Consequently, fluctuations in the macroeconomic environment are felt faster at Align than I've ever experienced anywhere in my career. And we monitor these trends to make adjustments in our business when needed. Our success is a result of our vision and purpose and resolve.
Invisalign 是一個獨特的大規模客製化業務,以即時方式運作,在市場前端沒有庫存或配送。因此,總體經濟環境的波動在 Align 的反映速度,比我職涯中在任何地方所經歷的都更快。我們也會監測這些趨勢,並在需要時對業務進行調整。我們的成功源自於我們的願景、使命與決心。
Thanks to our employees and our doctor customers around the world who took a chance on a Silicon Valley startup and risked everything. Today, Align is the largest 3D printing operation in the world, producing 1 million customized aligners each day based on the learnings gained from nearly 13 million Invisalign patients and 60 million iTero digital scans. Our global team of over 25,000 employees support more than 250,000 doctors and labs in more than 150 countries.
感謝我們的員工,以及全球的醫師客戶,他們願意相信一家矽谷新創公司並承擔一切風險。如今,Align 是全球最大的 3D 列印營運體系,每天生產 100 萬副客製化隱形牙套;這些成果建立在近 1,300 萬名 Invisalign 病患與 6,000 萬次 iTero 數位掃描所累積的學習之上。我們在全球超過 25,000 名員工的團隊,支援超過 150 個國家、逾 250,000 名醫師與實驗室。
There are more than 500 million people in the world that can benefit from orthodontic procedures. It's huge. And you can only address opportunities of that size with digital orthodontics. It could never happen using old analog methods. As we have digitized that capability, it has opened up a market broadly for orthodontic treatment to the masses.
全球有超過 5 億人可從齒顎矯正療程中受益。這個市場非常龐大。而要掌握如此規模的機會,只能依靠數位齒顎矯正;用傳統類比方法根本不可能做到。隨著我們將這項能力數位化,也讓齒顎矯正治療的市場得以更廣泛地向大眾開放。
It's hard to believe that after 25 years, we're still in the early phases of transforming the orthodontic market. We look forward to sharing more milestones over the next 25 years as we continue to lead the digital evolution of orthodontics and dentistry, deliver great treatment outcomes and treatment experiences to doctors and patients around the world.
很難相信 25 年後,我們仍處於改造齒顎矯正市場的早期階段。未來 25 年,我們期待分享更多里程碑;我們將持續引領齒顎矯正與牙科的數位演進,並為全球的醫師與病患帶來優異的治療成果與治療體驗。
Thank you for your time today. I'll now turn it over to the operator for questions. Operator?
感謝各位今天撥冗參與。接下來我把時間交給接線員進行問答。接線員?
Operator
Operator
(Operator Instructions) The first question is from the line of Jason Bednar with Piper Sandler.
(接線員指示)第一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
So Joe, I guess, just to start with you, I mean, you and John called out the consumer confidence items and the inflationary pressures impacting the business. The wind shifting pretty abruptly on you. I guess, are there tools you have at your disposal to manage through these pressures? Or is this a matter of just keeping your head down, waiting for the macro environment to settle down? I guess really just trying to get a sense of how we should be moderating expectations from what's typical sequential growth we would see from the business?
Joe,我想先從你開始。你和 John 都提到消費者信心以及通膨壓力對業務的影響,風向似乎相當突然地轉變。我想問的是,你們是否有工具可以用來因應這些壓力?還是說只能埋頭苦撐,等待總體環境穩定下來?我主要是想了解,對於我們通常會看到的逐季成長,你認為我們應該如何調整對成長的預期?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Jason, good question. I'd say being a global business, we talked about having 50% of our revenues outside, it just gives us good scope in the sense to take advantage where opportunities are. And so I feel really good about the company in that sense. And we've made great development over the last 3 years from an international standpoint.
是的,Jason,問得很好。我會說,作為一家全球性企業,我們談到有 50% 的營收來自海外,這讓我們在把握機會方面有很好的空間。因此在這方面我對公司很有信心。而且從國際市場的角度來看,過去 3 年我們也取得了很大的進展。
We also have a great portfolio. We have iTero scanners. We talked about some reluctance in the sense that we saw at the end of the first quarter of some doctors to really commit to it. But I mean that demand is still out there. When you look at iTero scanners are so under-penetrated still when you look at digital dentistry and what the future really brings. And so pushing that and pushing it in the right places, and also, you see the expansion of our Invisalign technology and what we're doing in different areas, too.
我們也有很強的產品組合,包括 iTero 掃描儀。我們提到在第一季末看到部分醫師在承諾採用方面有些猶豫。但需求仍然存在。當你看數位牙科的滲透率,以及未來真正會帶來的發展時,就會發現 iTero 掃描儀的滲透仍然很低。因此,我們會在正確的市場持續推動;同時你也看到我們 Invisalign 技術的擴展,以及我們在不同領域所做的事情。
So I feel like we have a lot of levers that we can pull, but we are constrained by these headwinds that we've seen. And obviously, we'll respect those and make the kind of adjustments needed to make sure this business stays on track. But look, I love our portfolio. I love our position. I see a great future. We'll manage our way through this, Jason.
所以我覺得我們有很多可以拉動的槓桿,但也確實受到我們所看到的逆風所限制。當然,我們會尊重這些因素,並做出必要的調整,確保業務維持在正軌上。不過你看,我很喜歡我們的產品組合,也很喜歡我們的市場位置。我看到很好的未來。我們會設法度過這段期間的,Jason。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Okay. All right. That's helpful. And then maybe shifting over to the margin side. You're not stepping off the gas with spending. I wouldn't expect you to, given the opportunity that you're talking about here today and you've talked about for quite some time. But I guess, are you still comfortable with that long-term model of 25% plus operating margins?
好的。了解,這很有幫助。接著可能轉到毛利率/利潤率這邊。你們並沒有在支出上踩煞車;考量到你今天談到的機會,以及你們長期以來一直在談的機會,我也不會預期你們會停下來。但我想問的是,你們是否仍然對長期模型中「25% 以上的營業利益率」感到有信心?
I know we've seen that for some select periods for the business. But is that the right margin level to think about for the business when you're driving towards that 20% top line growth? Just can you truly balance that? Or do you have to sacrifice one for the other, again, thinking longer term here?
我知道在某些特定期間你們曾達到過。但當你們推動營收年增 20% 的成長時,這仍是適合用來思考的利潤率水準嗎?你們真的能在兩者之間取得平衡嗎?還是必須犧牲其中一個?我再次強調是從更長期的角度來看。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think, Jason, honestly, I think we've managed that well over the years. I mean you can see how well we did last year in the sense of that operating profit has been squarely on top of that piece. And I think we've managed it within that bandwidth very well, and that's -- this current situation is not going to change that.
Jason,我坦白說,我認為我們多年來一直管理得很好。你可以看到去年我們的表現,營業利益在那一塊做得非常到位。我認為我們在那個區間內的管理一直很不錯,而目前的情況不會改變這一點。
Operator
Operator
The next question is from the line of Jeff Johnson with Baird.
下一個問題來自 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
So Joe, let me just pick up on that last point. I mean you said you've managed OpEx well over the years in that. I guess, let me just be direct on it. I mean if end markets are cyclically slowing, that's kind of out of your control, do you put the gas pedal down to the accelerator? Do you say, "Look, there's not a whole lot that, that's going to accomplish? So I kind of protect margins here in the short run." Just what's your OpEx outlook kind of in the near term -- near to intermediate term, I guess, given some of this macro uncertainty?
Joe,我接著你剛才那點問一下。你說多年來你們把營業費用(OpEx)管理得很好。我想更直接一點:如果終端市場正處於景氣循環式的放緩,而這又不在你們控制範圍內,你們會把油門踩到底嗎?還是會說:「看起來這樣做也不會有太大效果,所以短期先保護利潤率」?在目前這些總體不確定性下,你對近期到中期的 OpEx 展望是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, it's more the latter of your question. It's just you take off the accelerator. And we know -- John and I know where to adjust that won't hurt the business. We continue to invest in innovation in different areas, too. But there are several areas of short-term investments that aren't going to help us in this current crisis that we'll obviously lean into and make sure that we preserve margins as much as we can.
Jeff,比較接近你問題的後者,也就是把油門收回來。我們知道——我和 John 都知道——哪些地方可以調整而不會傷害到業務。我們也會持續在不同領域投資創新。但有幾個短期投資領域,在這次危機下不會對我們有幫助,我們顯然會在那些地方做取捨,並確保盡可能維持利潤率。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
But with those investments, yes, it will be -- when we talked about the 20-plus percent on a GAAP basis, that's the trade-off that we'll have. We'll invest where we can see a return and based on the volume that we expect, but deliver 20-plus percent op margin.
不過在這些投資之下,是的,當我們談到以 GAAP 基礎達到 20% 以上時,這就是我們要做的取捨。我們會在看得到回報、並且基於我們預期的量能之處投資,同時交付 20% 以上的營業利益率。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
And then a follow-up question, I guess, just on the Gaidge data, you talked about down 7% case starts ortho year-to-date. I'm hearing that through April, not just through March. But I don't get the whole Gaidge data set, but what I've seen is that the adult data is worse than the teen data, which would make sense to me. Everybody sitting at home, all the adults sitting home last year with the Zoom effect going on at this point and stimulus checks sitting in pockets and all that. So that all makes sense.
接著一個追問,關於 Gaidge 的數據。你提到今年迄今齒顎矯正的病例啟動數(case starts)下降 7%。我聽到的是這個數字是到 4 月為止,不只是到 3 月。不過我沒有完整的 Gaidge 資料集;但我看到的部分顯示成人的數據比青少年更差,這對我來說也合理。去年大家都待在家裡,成人都在家,Zoom 效應在那個時間點發酵,加上刺激支票在口袋裡等等,所以這些都說得通。
But just what's the tenor in North America or in those markets that aren't impacted by China and Russia, Ukraine in that, what's the tenor of the teen business? And is the core, that part of the business, still doing better than you've just got real tough comps because all those adults were coming in last year as they were sitting at home and had nothing better to do than go get clear aligners?
但在北美或那些未受中國、俄羅斯與烏克蘭影響的市場,青少年業務的氛圍如何?核心的那部分業務是否仍表現較好,只是因為去年成人在家、沒事做就去做透明牙套,導致今年比較基期很難?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, it's Joe. Look, the teen market, you're good to focus on that. I mean that's -- we look at that as a fairly secure market. Obviously, it can move up and down, but it won't have the volatility that you've seen in the adult market. And you comparing it against last year is a good way to look at it, given the Zoom effect and things we talked about before. So -- I mean, Jeff, that's why you see us launching these teen products right now and getting ready from a summer time standpoint.
Jeff,我是 Joe。你把焦點放在青少年市場是對的。我們把那視為相對穩健的市場。當然它也會上下波動,但不會像成人市場那樣出現你所看到的波動性。你用去年來做比較也是很好的方式,考量到 Zoom 效應以及我們之前談過的因素。所以——Jeff,這也是為什麼你看到我們現在推出這些青少年產品,並從暑期檔期的角度做準備。
We want to take advantage of that demand as much as we possibly can, especially in times like this. We know the adult market is going to be pressured. And I'm talking about the U.S. right now, but let's leave China out, because China is in a unique position in the sense of a lockdown that they're going through. But we're -- you're going to see us take the same tact in Europe also. And you saw our teen volume in Europe was actually pretty good in the first quarter.
我們希望盡可能充分利用那股需求,尤其是在像現在這樣的時期。我們知道成人市場將會承受壓力。我現在談的是美國,但先把中國排除在外,因為中國正處於一個獨特的情況,也就是他們正在經歷封控。不過我們——你們也會看到我們在歐洲採取同樣的策略。而且你們也看到,我們在歐洲的青少年量在第一季其實相當不錯。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
What about that teen volume in the U.S., Joe?
那美國的青少年量呢,Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We expect that teen volume to be good. Summer seasonality is there. And it's funny, there's a window for teens to really have their teeth treated. And we've known that here for years, and that's why we've prepared for teen season. And this year, honestly, Jeff, I feel better about our positioning for teens in United States and also in Europe than I have any time since I've been here, with these teen packs that we just talked about and how we'll go about it. I think we're well positioned to make further penetration in the teen market versus wires and brackets.
我們預期青少年量會表現良好。夏季的季節性因素在那裡。而且很有趣的是,對青少年而言,確實有一個適合進行牙齒矯治的時間窗口。我們多年來在這裡就知道這點,所以我們才會為青少年旺季做準備。而今年,老實說,Jeff,我對我們在美國以及歐洲的青少年布局,比我在這裡任職以來任何時候都更有信心,因為有我們剛剛談到的這些青少年套裝方案,以及我們將如何推進。我認為相較於鋼絲與托槽,我們已經做好充分準備,能在青少年市場進一步提高滲透率。
Operator
Operator
The next question is from the line of Jonathan Block with Stifel.
下一個問題來自 Stifel 的 Jonathan Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
A good segue, I'll start with the teen case packs. We picked up on that program right after April. Quite honestly, unfortunately, I'm old enough to remember your teens pack programs internationally from like a decade ago. And if I remember those correctly, Joe, it is just hard to collect, if you would, if someone did below their threshold. And hopefully, I'm making some sense. So maybe just talk to us -- here you are going after it and you're going after teens, not overall. You're launching it. What's going to be different this go-round?
很好的銜接,我先從青少年病例套裝(teen case packs)開始。我們在四月之後就注意到那個方案。坦白說,不幸的是,我年紀大到還記得你們大約十年前在國際市場推出的青少年套裝方案。如果我沒記錯的話,Joe,那個方案在收款上很難處理——如果有人做不到他們的門檻,你們就很難去「收」那筆錢。希望我表達得清楚。所以能否請你談談——你們現在又要再做一次,而且是鎖定青少年而不是整體市場,你們要推出它。這一輪會有什麼不同?
When someone commits to a 50-case pack or a 100-case pack, let's go with 100, they do 88 and you've got to go out there and say, "Hey, look, it's a use it or lose it. We've got to collect for you." And then also just keep the tenor of the relationship or the goodwill of the relationship intact, because now, arguably, they even have more options to go somewhere else versus what they were staring down a decade ago. So maybe if you could talk to that and just the timing behind kicking off the program, that would be a great place to start.
當有人承諾買 50 例套裝或 100 例套裝——我們以 100 例為例——結果他只做了 88 例,你們就得去跟他說:「嘿,你要不用就作廢(use it or lose it)。我們得向你收款。」同時還要維持關係的基調或彼此的善意,因為現在可以說,他們相較於十年前,轉去別家的選擇更多。所以如果你能談談這點,以及啟動這個方案背後的時機考量,會是一個很好的開始。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
So you're like an Align historian, that's a good question, right? Because I can tell you, I wasn't here when that happened in Europe, but it's legendary here. But if you go back in time, I think our business in Europe was less than $10 million back then, okay? Now it's over $1 billion. And I think the whole world is much more acquainted with clear aligners than when it was back then. We were really pioneers at that point in time.
所以你算是 Align 的歷史學家了,這是個好問題,對吧?因為我可以告訴你,當年歐洲發生那件事時我不在,但在公司內部那是個傳奇。不過如果回到當時,我想我們在歐洲的業務那時還不到 1,000 萬美元,對吧?現在已經超過 10 億美元。而且我認為,全世界對透明矯正器的認知也比當年高得多。那時我們真的是先行者。
If you look at our DSP program, it's basically the same thing. They make commitments of how many aligners they're going to buy over a certain period of time. We haven't had any issues in DSP with having customers regress or not making those benchmarks. So we feel pretty good about where we are. I mean will we run into a few situations, I think we will. I think they'll be outliers, and we'll deal with them in time.
如果你看我們的 DSP 計畫,基本上是同樣的概念。他們承諾在某一段期間內要購買多少副矯正器。我們在 DSP 上沒有遇到客戶倒退或無法達成那些門檻的問題。所以我們對目前的狀況相當有信心。我的意思是,我們會不會遇到少數情況?我想會的。我想那會是少數例外,我們會在適當時候處理。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Fair enough. And I just might go back to sort of where Jason started a little bit. There's going to be a lot of questions on 2022 and pulling the top line guidance. So let me just throw out a couple of things, and we could sort of work through it. If I look back to the past 5 to 6 years, the first quarter was about 22% of total revenue. And if you run that exercise for this year, you get about 11% or 12% year-over-year revenue growth and you've got an incremental FX headwind. So should we throw a dart at 10%? And what's wrong with that thought process in getting to, call it, low double-digit 10%, 12% top line growth for '22?
好,可以理解。我也想回到 Jason 一開始提到的部分。大家會對 2022 年以及撤回營收指引有很多問題。所以我先拋出幾個點,我們可以一起推演。如果我回看過去 5 到 6 年,第一季大約占全年營收的 22%。如果用這個比例去推算今年,你會得到大約 11% 或 12% 的年增營收成長,另外還有額外的匯率(FX)逆風。所以我們是不是可以先抓個 10%?這樣的推理哪裡有問題?也就是說,為什麼不能推到 2022 年營收年增大概低雙位數、10% 到 12%?
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
I think -- Jon, this is John. As we talked about that last earnings, there was a lot of changes that have happened in the marketplace and in the world. And as a result of that, we pulled the top line guidance until we get further clarity as to how things are going to shake out. What we have committed to is being able to grow in a profitable way, in a way that you would expect us to be responsible being at 20-plus percent. But we pulled that guidance because of the uncertainty.
我想——Jon,我是 John。正如我們在上次財報電話會議談到的,市場與世界發生了很多變化。也因此,我們撤回了營收端(top line)的指引,直到我們對事情將如何發展有更清楚的掌握。我們承諾的是能以獲利的方式成長,以你們期待我們負責任的方式,在 20% 以上的水準。但我們撤回指引是因為不確定性。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, just to add to John's comments, too, is that as we look at April versus March, we haven't seen any momentum from an April standpoint, too. And we start from that standpoint also.
Jon,再補充 John 的評論:當我們看四月相較於三月時,從四月的角度來看,我們也沒有看到動能。我們也會從這個角度作為出發點。
Operator
Operator
The next question is from the line of Erin Wright with Morgan Stanley.
下一個問題來自 Morgan Stanley 的 Erin Wright。
Erin Elizabeth Wilson Wright - Equity Analyst
Erin Elizabeth Wilson Wright - Equity Analyst
In the Americas -- good to hear from you. So in the Americas, can you parse out a little bit about what you're seeing in terms of macro headwinds compared to maybe some of the lingering COVID impact? And does it seem like some -- I mean it doesn't seem like some of these cases are coming back from maybe Omicron delays. But what are you seeing in terms of the dynamics there? Just trying to kind of parse out. Last quarter, you did break out kind of a COVID impact, but could you do that this quarter?
在美洲地區——很高興聽到你們的分享。所以在美洲,你能不能再拆解一下,你們看到的逆風中,宏觀因素相較於一些仍在延續的 COVID 影響,各自大概是什麼情況?而且看起來——我的意思是,看起來有些病例並沒有因為 Omicron 延遲而回流。但你們看到的動態是什麼?我只是想把它拆開來看。上季你們確實有把 COVID 的影響單獨拆出來,但這一季你們也能這樣做嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
It's hard to be very discrete in the sense of what that impact is, Erin. But I'd say we obviously faced staffing shortages and things at different doctors in the first part of the first quarter that affected us. I'd say that drifted through to basically late February, early March. After that, you can -- if you watch the consumer confidence statistics in the United States, they've gone down pretty dramatically. And we started getting a lot of reports from our doctors that a patient is not saying no, but the patient is not as quick to say, yes, that they want a treatment.
要非常明確地切分那個影響其實很難,Erin。但我會說,我們在第一季前半段確實面臨人力短缺等問題,在不同診所端對我們造成影響。我會說那個情況大致延續到二月下旬、三月上旬。之後,如果你去看美國的消費者信心統計數據,已經相當明顯地下滑。我們也開始從醫師那裡收到很多回報:病患不是說不做,但病患沒有那麼快就說「好,我要做治療」。
And we hear that both in the GP segment and the orthodontic segment. So you can call that what you want to, okay? But we see some reticence in the marketplace to move forward with treatment. And again, it's not binary. It's not everybody is saying no, like in the heart of a deep recession or something we saw back in '07 or '08. It's just more cautiousness from people about their personal finances.
而且我們在一般牙醫(GP)與矯正專科兩個區隔都聽到同樣的情況。所以你要怎麼稱呼都可以,好嗎?但我們看到市場對於推進治療有一些猶豫。再說一次,這不是二元的。不是每個人都在說不,像是深度衰退的核心期、或像我們在 2007 或 2008 年看到的那樣。只是人們對自己的個人財務更謹慎。
Erin Elizabeth Wilson Wright - Equity Analyst
Erin Elizabeth Wilson Wright - Equity Analyst
Okay. Great. And then on ASPs for the balance of the year, I guess, how should we be thinking about that and the levers, I guess, you can pull on that front?
好,了解。那關於今年剩餘時間的 ASP(平均售價),我們應該怎麼看?以及我想,你們在這方面可以操作的槓桿有哪些?
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Erin, this is John. From an overall ASP standpoint, we don't have anything unusual from a promotion standpoint or anything else that would affect us. Obviously, notwithstanding FX, we've seen unfavorable FX as we've gone through this year so far. But notwithstanding FX, we wouldn't expect anything dramatically different from an ASP standpoint.
Erin,我是 John。就整體 ASP 而言,我們沒有任何不尋常的促銷或其他會影響我們的因素。當然,匯率(FX)除外——截至目前今年我們確實看到不利的匯率影響。但撇除 FX,我們不預期 ASP 會有任何顯著不同。
Operator
Operator
The next question is from the line of Kevin Caliendo with UBS.
下一個問題來自 UBS 的 Kevin Caliendo。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
So I guess the question I have is -- the first one is really why have the doc starts been so sluggish? Is it demand-driven? Is it competitive positioning? Is it -- I would just love to hear sort of why, in the U.S. especially, the sort of doc adds have been flattish for the last couple of quarters? If there's anything, if it's macro or micro or competitive?
所以我想問的是——第一個問題是,為什麼醫師端啟動(doc starts)會這麼疲弱?是需求驅動嗎?是競爭定位嗎?還是——我很想聽聽原因,尤其在美國,為什麼過去幾個季度醫師新增(doc adds)一直相對持平?有沒有什麼因素,是宏觀、微觀或競爭面的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I think I read your question. I think you're asking if it's competitive, because I mean, we're pretty clear on what we've been seeing around the globe and the United States from a macro standpoint, Kevin. So I just -- look, from a competition standpoint, we don't see any major issue with competition in the sense of being a factor in this demand cycle that we're talking about.
嗯,我想我理解你的問題。我想你是在問是不是競爭因素,因為從宏觀角度來看,Kevin,我們對全球以及美國目前看到的情況其實講得很清楚。所以我只是——你看,就競爭而言,我們沒有看到任何重大競爭問題,會在我們正在談的這一輪需求循環中成為主要因素。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
And when we try to think about the impacts here that are driving all of this, how much do you -- have you guys been able to ascertain how much of this is economic-driven? You're talking about decisions taking longer and people being more hesitant and volumes being down. How much of that is economic versus COVID versus other?
而當我們試著思考推動這一切的影響因素時,你們——你們能判斷出其中有多少是經濟因素驅動的嗎?你們提到決策時間拉長、人們更猶豫、量在下滑。這裡面有多少是經濟因素、多少是 COVID、多少是其他因素?
Like have you been able to just parse out what's really driving it as a percentage? Is it mostly simply, listen, we're in an inflationary environment, people don't have as much to spend, consumers aren't spending as much broadly versus just an overall demand for your products and/or COVID, like those 3 things, if you were to group them?
像是你們是否能夠把真正驅動因素以百分比拆解出來?主要是不是很單純地說,我們處在通膨環境,人們可支配支出變少,消費者整體支出下降;相較之下,還是說主要是你們產品的整體需求,以及/或者 COVID——如果把它們分成這 3 件事來看?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Kevin, our announcement and the way we communicate to the marketplace, we talk about this huge market, right? We're totally under-penetrated in the orthodontic segment, less than 10% of 21 million case starts a year, talk about what we see through the 500 million patients. So there's not a lack of demand out there and the lack of opportunity. There's not a competitive issue that we think is affecting our growth or our earnings.
Kevin,我們的公告以及我們對市場的溝通方式,是在談這個龐大的市場,對吧?我們在齒顎矯正領域的滲透率仍然非常低,每年 2,100 萬個起始病例中不到 10%,也談到我們在 5 億名患者中所看到的情況。所以外部並不存在需求不足或機會不足。我們也不認為有競爭面的問題在影響我們的成長或獲利。
And so obviously, COVID is part of this thing. Part of what we see in Europe was the Ukraine conflict that's going on today. And I think a significant amount of it is, too, is what we're seeing in the marketplace, too, from a consumer standpoint. I can't put any weighted averages on these things to give you an example.
因此很明顯,COVID 是其中一部分。我們在歐洲看到的一部分因素,是今天仍在進行的烏克蘭衝突。我認為其中相當大的一部分,也來自我們在市場端、從消費者角度所看到的情況。我無法替這些因素給出任何加權平均來舉例說明。
And I think -- if I compare to -- when we last talked to you at the first couple of days of February, the way things have changed, those variables in that equation, I think, have changed pretty dramatically. So it's really hard to say going forward what that might be.
而且我想——如果我拿來比較——我們上次在 2 月初的前幾天和你們溝通時,事情的變化方式、那個方程式裡的變數,我認為已經相當劇烈地改變了。所以很難說未來會怎麼走。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Are there any goals that you have -- one last one from me. Are there any goals that you have for this year in terms of quantifiable goals in terms of whether it be doc adds or utilization uptick or -- I mean I know those are the things you were focused on when you talked about increasing your spend. Like what are you targeting at this point? Is there anything that we can sort of put a stick in the ground and say, "Okay, here is something that the company is hoping to achieve in 2022 in terms of a quantifiable number."
我最後再問一個。你們今年有沒有任何目標——一些可量化的目標?不管是新增醫師數、使用率提升之類的——我的意思是,我知道你們在談到增加支出時,重點就在這些事情上。你們目前的目標是什麼?有沒有什麼我們可以算是「插一根旗子」說:「好,這是公司在 2022 年希望達成的某個可量化數字」?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Kevin, this is a growth company, and it never leaves our thought process. So what are we trying to do? We're trying to run the play we always do. We're running these plays in a much more difficult market with more headwinds. That's all. And so we'll move these plays around. We'll look at them by country. We'll see what makes the most sense. We still keep a good strong focus on how we can grow and where we can grow, and we'll find those ways.
Kevin,我們是一家成長型公司,這從未離開過我們的思考。那我們想做什麼?我們想做的就是照我們一貫的打法去執行。我們只是在一個更困難、逆風更多的市場裡跑同樣的戰術,就這樣。所以我們會調整這些戰術;我們會按國家來看;我們會看什麼最合理。我們仍然會強力聚焦在如何成長、在哪裡成長,我們會找到那些方法。
Operator
Operator
The next question is from the line of Michael Ryskin of Bank of America.
下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
I've got 2 I want to touch on. Can you hear me?
我有兩點想談。你聽得到我嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes.
聽得到。
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
One is just sort of talking through some of the dynamics we're talking to -- you talked for the quarter. I think we can all kind of see that a lot of it is macro-driven, a lot of it's global-driven and each of these events that we're following, whether it's the China lockdowns or the conflict in Europe or even things like FX are going to be more temporary than others. I know your long-term outlook is still there for the 20% to 30% volume growth and revenue growth. But what about sort of catch-up spend on these things?
第一點是,想再談談你們這一季提到的一些動態。我想大家都看得出來,其中很多是由總體因素驅動、很多是全球因素驅動;而我們在追蹤的每一個事件,不管是中國封控、歐洲衝突,甚至像匯率(FX)這類因素,有些會比其他因素更偏短期。我知道你們的長期展望仍然是銷量成長與營收成長 20% 到 30%。但那麼,關於這些事情的「補回來的支出」呢?
Is there an expectation somewhere -- and you kind of touched on this when you talked about your spend and your expectations on investment this year. As we go through the next couple of months, next couple of quarters as some of these things start to fade, are you expecting another bolus of catch-up as these cases come back like we saw in 2020 and 2021? Anything you can sort of comment on that? And then I've got a follow-up.
是否在某個地方存在一種預期——你在談到今年的支出與投資預期時也稍微提到——隨著未來幾個月、幾季一些因素開始消退,你們是否預期會出現另一波「補回來」的量,像我們在 2020 與 2021 年看到那些病例回流一樣?你能否就此做一些評論?然後我還有一個追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think a bolus you talked about -- I mean, that was interesting is what we saw after the last downturn, it was first like COVID. I mean I look at that, Mike, overall, is it just shows you the demand out there for our kind of procedures. So it's there. And so John and I aren't sitting here, predicting another bolus or a wave or whatever, but I think it just shows you the demand that exists in this business, and it can be pent up at times. We'll just have to see how the headwinds that we see filter through the marketplace and how it affects consumers and doctors.
我想你提到的那一波——我的意思是,那很有意思:我們在上一次下行之後看到的情況,最初就是 COVID。我整體來看,Mike,那其實只是顯示出市場對我們這類療程的需求確實存在。所以需求在那裡。John 和我不會坐在這裡去預測會再來一波或一個浪潮之類的,但我認為那只是顯示這個產業存在的需求,而且有時候會被壓抑。我們只能看看我們看到的逆風如何在市場中傳導,以及它如何影響消費者與醫師。
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
Michael Leonidovich Ryskin - Director in Equity Research & Research Analyst
And then the follow-up, you touched on this in an answer earlier when you sort of referenced the 2007, 2008 downturn. Obviously, hopefully, we're not going to something quite like that in the coming year, too. But there's still a lot of talk about recession and sort of what the impact of prolong inflation is going to be on the consumer. Could you talk us through your plans if things do continue to deteriorate on that front?
接著追問,你先前在回答中提到 2007、2008 年的下行。當然,希望我們未來一年不會走到那種程度。但市場上仍有很多關於衰退的討論,以及長期通膨對消費者會造成什麼影響。若那方面的情況持續惡化,你們能否談談你們的計畫?
I mean we're not there yet, but 6 months from now, a year from now, things are still heading in that direction, sort of what are your internal plans for adjusting both on operations side? How will you sort of position yourself for growth in that kind of environment? Because if you look back at 2007, '08, '09, there was a protracted period of essentially flat growth. So could you compare and contrast that?
我的意思是,我們現在還沒到那一步,但如果 6 個月後、1 年後,事情仍朝那個方向走,你們內部在調整營運面上有哪些計畫?在那種環境下,你們會如何為成長做定位?因為回頭看 2007、'08、'09,那是一段相當長的、基本上成長持平的期間。你們能否做個對照與比較?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, it's Joe again. I just -- we have a really strong balance sheet to start with. It's great to have a strong balance sheet and really no net debt from a company standpoint. So look, I'm not an economist, but I'm not predicting a meltdown of our financial system like we saw in 2007, 2008. Depending on what Federal Reserve does or whatever, how we're going to see this adjustment as they try to attack inflation.
是的,我是 Joe。我只是——我們一開始就有非常強健的資產負債表。從公司角度來看,擁有強健的資產負債表、幾乎沒有淨負債是很棒的。你看,我不是經濟學家,但我不會去預測像 2007、2008 年那樣的金融體系崩潰。至於聯準會會做什麼等等,我們會如何看到這種調整、他們如何試圖對抗通膨。
So look, we -- this business is incredibly healthy. It generates a lot of cash. It's extremely international now. And we have a lot of levers to pull and a lot of things to do to keep this business going. So -- but if something dire did happen, I feel we've got a balance sheet to be able to cover it, too, and we'll manage the business responsibly that way.
所以你看,我們——這個業務非常健康。它產生大量現金。現在也非常國際化。我們有很多可以拉動的槓桿、很多事情可以做來讓業務持續運轉。所以——但如果真的發生嚴重狀況,我覺得我們也有資產負債表能夠承受,我們也會以負責任的方式來管理這門生意。
So I'd just tell you, don't give up on us, okay? We love this business. We love the position that it's in. We're confident about the future. We're just going to see how these headwinds hit and how they subside, and we'll be ready on either end of that to be able to position this company to do well.
所以我只想告訴你們,別放棄我們,好嗎?我們熱愛這門生意。我們喜歡它目前所處的位置。我們對未來有信心。我們只是要看看這些逆風會如何衝擊、又會如何消退,而我們會在兩端都做好準備,讓公司能夠在其中取得良好定位、表現出色。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
And I might add, just we are a different business than we were back in 2007, 2008. We didn't have iTero. We have iTero, much more of a global business, better products, much further along in the teen market, more consumer awareness. All the things that we've done over this time period now being 25 years, we've evolved over time and created a business where we're very mindful of what is happening from a demand standpoint, and we can do a lot of things from a leverage standpoint in order to drive that right amount of profitability.
我再補充一點:我們現在的業務,和 2007、2008 年時已經不同了。那時我們沒有 iTero。現在我們有 iTero,業務更全球化、產品更好、在青少年市場走得更前面、消費者認知更高。過去這段時間——現在已經 25 年——我們做的所有事情,讓我們隨時間演進,打造出一個非常留意需求面變化的業務;而且我們也能從槓桿運用的角度做很多事,以推動適當的獲利水準。
Operator
Operator
The next question is from the line of Nathan Rich with Goldman Sachs.
下一個問題來自高盛(Goldman Sachs)的 Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
I wanted to follow up on your commentary on April and not seeing momentum return. I was just wondering if there's any parameters you could put around that relative to maybe what you've seen in the first quarter? I guess like would that sort of mean volumes more flattish, anything that you could do to kind of help us think about how the business kind of exited the first quarter and where the current run rate is would be helpful.
我想追問你們對 4 月的評論,也就是沒有看到動能回來。我想知道,你們能否就此提供一些界定參數,對照可能第一季你們看到的情況?我的意思是,這是否代表量更偏持平?你們能否提供一些資訊,幫助我們理解公司在第一季結束時的狀態,以及目前的運行速度(run rate)?這會很有幫助。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Nate, I'll give you a quick rundown, and John can give you specifics, too. Look, we -- this is flattish to use your term. When you look at between March and April is more flattish than anything. But just remember, we have -- China is still our second biggest country in the world. It's locked down. Shanghai -- Beijing is going into lockdown. And that's not the first lockdown we've seen in China.
可以。Nate,我先快速說明一下,John 也可以補充細節。你看,我們——用你的詞來說,就是偏持平。當你看 3 月到 4 月之間,與其說別的,不如說更偏持平。但請記得,我們的——中國仍然是我們全球第二大國家。它正在封控。上海——北京也正在進入封控。而且這也不是我們在中國看到的第一次封控。
Remember, there are several provinces that were locked down before that, too. So that part of our business has really been impacted in a big way, and that's part of that flattishness that we're talking about, too. So we're seeing impact in every region of the world, but in different ways. And on the APAC side, particularly with China, it's dramatic.
請記住,在那之前也有好幾個省份已經封城。所以我們那部分業務確實受到很大程度的影響,而這也是我們所談到那種持平狀態的一部分。因此,我們在全球每個地區都看到影響,但方式各不相同。而在亞太(APAC)方面,尤其是中國,影響非常劇烈。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
I don't have much -- anything to add to it. It's just -- a lot has changed, as we've seen, over the last couple of months, and we're responding to that change.
我沒有太多——任何補充。只是——正如我們所看到的,在過去幾個月裡很多事情都改變了,而我們也在因應這些變化。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Makes sense. And I guess, I'd be curious just to get your thoughts on sort of the consumer environment. I know it's been touched on in other questions. But Invisalign treatment is a higher ticket purchase, and we've kind of always thought of it as catering to a more affluent consumer.
有道理。我想我也很好奇想聽聽你對消費者環境的看法。我知道在其他問題中也有提到。不過 Invisalign 療程屬於較高單價的消費,我們一直認為它主要是面向較富裕的消費者。
I guess is there anything that you've seen kind of between higher-end consumer versus lower-end consumer? And they're going back to, I think, the way you framed it, kind of the reticence to start treatment. Any difference that you've seen among maybe the different segments of the population that could be considering treatment?
我想問的是,你是否看到高端消費者與低端消費者之間有任何差異?再回到你剛才的說法,也就是對開始療程的猶豫。你是否在可能考慮接受療程的不同人群區隔之間,看到任何差異?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I commented back to the other question, was asked about teens, right? The teen aspect in the orthodontic segment is pretty resilient, and that is a certain demographic that's always existed in the sense of the parents that they can afford that kind of treatment for young children. The adult segment, it's all over the place depending on -- sometimes, it's just teeth straightening. Some of the times, it's a broad orthodontic correction of what's going on.
我在回覆另一個問題時提到過,有人問到青少年,對吧?在矯正市場中,青少年這一塊相當有韌性;這是一個一直存在的特定族群,因為有些家長有能力負擔年幼孩子的這類治療。成人族群則差異很大,取決於——有時只是牙齒排列矯正;有時則是針對現況進行較全面的矯正治療。
We don't have any data in that adult segment to say that a certain score of certain -- by the score of certain much -- a certain amount would be fewer people taking treatment or whatever. I don't have that data. I don't know if John has seen it either. But you'd have to guess that the more your finances are impacted, the less you're going to sign up for a $3,500 to $7,000 treatment depending on what you want or how you're in a contract for it. So it's logical that certain demographics would be less willing at this point in time.
我們在成人族群方面沒有任何數據可以說,某個分數或某些——以某些分數來看——會有多少人更少去接受治療之類的。我沒有那樣的數據。我也不知道 John 是否看過。不過你可以推測,財務受影響越大,你就越不會去報名一個 3,500 到 7,000 美元的療程,取決於你想要什麼,或你如何簽訂合約。因此,從邏輯上來說,某些族群在此時此刻會更不願意。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Operator, we'll take one more question, please.
接線員,請再讓我們接一個問題。
Operator
Operator
Absolutely. The next question is from the line of Elizabeth Anderson with Evercore ISI.
當然。下一個問題來自 Evercore ISI 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
So maybe one question on the iTero scanner growth. Obviously, we saw a deceleration quarter-over-quarter, but still year-over-year growth there. When you sort of talk about how providers are looking at demand -- and I realize that not all of that is like pure like iTero sales. How do we think about sort of what's driving the purchases in the first quarter?
我想問一個關於 iTero 掃描儀成長的問題。顯然,我們看到季度對季度有所放緩,但年對年仍有成長。當你談到醫療提供者如何看待需求——我也理解其中不全然是純粹的 iTero 銷售——我們該如何理解第一季購買行為背後的驅動因素?
Obviously, there is some seasonality. But if you like, overall visits, maybe ex clear aligners are not -- has -- maybe haven't been quite as impacted. Are we seeing sort of a reticence to spend? Is it sort of interest rates going up and people worried about sort of equipment financing? Could you walk us through some of the puts and takes of the demand drivers there?
顯然有一些季節性因素。但如果你看整體就診量,也許不含透明牙套(clear aligners)的部分並沒有——或許沒有受到那麼大的影響。我們是否看到某種不願意支出的情況?是否是利率上升、大家擔心設備融資?你能否帶我們梳理一下那裡需求驅動因素的利弊權衡?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Elizabeth, it's Joe. I'd start with, still the market is broadly unpenetrated from a scanner standpoint. GP side, the ortho side. In ortho, that does a lot of Invisalign. They can have 4, 5, 6 scanners overall. So look, I've been with the GE Healthcare for years, ABB. I understand the capital equipment cycle. There is a true cycle in capital equipment. When people get concerned, they'll delay those kinds of purchases.
Elizabeth,我是 Joe。我會先從這點開始:就掃描儀而言,市場整體仍然滲透率很低,無論是全科牙醫(GP)端或矯正端。在矯正端,如果做很多 Invisalign,他們整體可能會有 4、5、6 台掃描儀。你看,我在 GE Healthcare、ABB 待過很多年,我了解資本設備週期。資本設備確實有其週期。當人們感到擔憂時,就會延後這類採購。
And I think, obviously, we have, what I would talk about, 250,000 doctors that we service today. Some of them are going to be worried about what their cash flow is going to look like. They're going to be reticent in the sense of saying they want to sign up for a scanner that can cost anywhere between $15,000 to $35,000 right now and what we sell.
而且我認為,顯然我們目前服務大約 250,000 位醫師。其中一些人會擔心他們的現金流會變成什麼樣子。他們會有所遲疑,因為他們要決定是否要購買一台掃描儀,而我們目前銷售的價格大約在 15,000 到 35,000 美元之間。
So I can't tell you by country or by region or whatever, but we didn't see things shut off. We just saw things, as the quarter got through, we just didn't have as strong as demand for iTero than we anticipated. So we'll have to -- obviously, we get into this quarter. We'll continue to watch it and see which way it goes. But there's going to be some more scrutiny, I think, around capital investment if doctors are seeing less traffic through their practices.
所以我無法按國家或地區等來告訴你,但我們沒有看到需求突然中斷。我們只是看到,隨著季度推進,iTero 的需求沒有我們預期的那麼強。因此我們必須——顯然進入本季度後,我們會持續觀察並看走向如何。但如果醫師看到診所來客量下降,我認為他們在資本投資上會有更多審慎與檢視。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Yes. It's just the delays that they put to not close unnecessarily within the quarter. It's not going away, but it's just a delay. And we have to work to try to get them to say yes.
是的。只是他們把決策延後了,並不是在季度內不必要地把案子關掉。需求不會消失,只是延遲。而我們必須努力讓他們點頭同意。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
And you're not having any supply chain issues on that side in terms of being able to manufacture the equipment?
那在供應鏈方面,你們在製造設備的能力上沒有任何問題嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We didn't have any in the first quarter. We won't have any in the second quarter either.
第一季沒有,第二季也不會有。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Okay. And one more quick follow-up. In terms of the gross margin impact of the new Poland facility, can you remind us about the cadence of the gross margin pressure when you open a new facility as it scales? I'm just trying to be able to parse that out versus maybe some of the deleveraging impact of some of the volume shifts versus that.
好的。再一個很快的追問。關於波蘭新廠對毛利率的影響,你能提醒我們一下,新廠啟用並逐步放量時,毛利率壓力的節奏是怎樣的嗎?我想把這部分與可能因出貨量變動造成的槓桿下降影響區分開來。
John F. Morici - CFO & Executive VP of Global Finance
John F. Morici - CFO & Executive VP of Global Finance
Yes, Elizabeth. What we'll see is we'll go live in the second quarter here, and that does have a gross margin impact. It really comes down to trying to get as much utilization through the plant as possible, moving those countries and doctors through the plant. And then once that utilization increases, then you start to see some of that productivity. So it hits about a quarter, maybe a little bit more than a quarter, and then it subsides and then it gets more on a regular operating basis.
好的,Elizabeth。我們會在第二季正式上線,而這確實會對毛利率造成影響。關鍵在於盡可能提高工廠的產能利用率,把那些國家與醫師的訂單轉到該工廠生產。當利用率提升後,你就會開始看到部分生產力改善。因此大約會影響一個季度,可能略多於一個季度,之後就會緩解,並回到較正常的營運水準。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thanks, Elizabeth. Well, thank you, everyone, for joining us today. This concludes our conference call. We look forward to speaking to you at upcoming conferences and industry meetings. And if you have any questions, please contact Investor Relations. And have a great day.
謝謝你,Elizabeth。也謝謝各位今天加入我們。本次電話會議到此結束。我們期待在接下來的各項會議與產業活動中與各位交流。如有任何問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
This concludes today's conference. You may now disconnect your line at this time. Thank you for your participation.
今天的會議到此結束。您現在可以掛斷電話線。感謝您的參與。